Partners Wealth Management LLC Purchases New Position in Moderna, Inc. $MRNA

Partners Wealth Management LLC acquired a new stake in Moderna, Inc. (NASDAQ:MRNA) in the third quarter, Holdings Channel reports. The fund acquired 4,013 shares of the company’s stock, valued at approximately $773,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Moderna during the second quarter worth approximately $2,142,877,000. Theleme Partners LLP bought a new position in shares of Moderna in the 2nd quarter worth $564,272,000. Wellington Management Group LLP lifted its holdings in shares of Moderna by 4.4% in the 2nd quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock worth $172,384,000 after purchasing an additional 103,977 shares in the last quarter. First Trust Advisors LP lifted its holdings in shares of Moderna by 59.3% in the 1st quarter. First Trust Advisors LP now owns 2,392,693 shares of the company’s stock worth $121,549,000 after purchasing an additional 891,072 shares in the last quarter. Finally, Merck & Co. Inc. acquired a new stake in Moderna in the 2nd quarter valued at $161,642,545. Institutional investors own 75.33% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Loop Capital set a $135.00 price target on shares of Moderna in a research note on Wednesday, August 19th. Evercore upped their price objective on shares of Moderna from $50.00 to $80.00 in a report on Thursday, October 8th. TD Cowen reaffirmed a “buy” rating on shares of Moderna in a research note on Wednesday, October 21st. Argus upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $180.00 price objective for the company in a report on Friday, August 28th. Finally, William Blair cut shares of Moderna from an “outperform” rating to a “market perform” rating in a report on Tuesday. Six analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $107.10.

Moderna Price Performance

Shares of NASDAQ:MRNA opened at $221.72 on Friday. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09. The stock’s fifty day simple moving average is $182.49 and its two-hundred day simple moving average is $86.52. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $254.48. The stock has a market cap of $88.52 billion, a PE ratio of -27.75 and a beta of 1.09.

Moderna (NASDAQ:MRNA) last posted its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The firm had revenue of $145.00 million during the quarter, compared to analyst estimates of $102.93 million. During the same quarter in the prior year, the business posted ($2.13) EPS. The business’s revenue was up 2.1% compared to the same quarter last year. As a group, analysts forecast that Moderna, Inc. will post -6.11 EPS for the current fiscal year.

More Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna’s personalized cancer-vaccine candidate remains a key potential catalyst. Recent clinical data have encouraged investors, and Chief Executive Stéphane Bancel defended the melanoma results, saying the data could improve over time and that competitors may not easily replicate the company’s technology. Will Moderna Soar on Nov. 6? Moderna’s CEO discusses its cancer vaccine
• Positive Sentiment: Coverage comparing Moderna with BioNTech highlights the company’s oncology platform and its potential role in the growing mRNA cancer-vaccine market. Successful follow-up data could support Moderna’s long-term growth narrative. Moderna cancer results versus BioNTech
• Neutral Sentiment: Investor attention is elevated ahead of Moderna’s quarterly earnings release. The report may provide updated financial guidance and more information about the company’s pipeline, but heavy searches alone do not change the underlying outlook. Moderna projected to announce quarterly earnings
• Negative Sentiment: Analysts expect Moderna’s third-quarter earnings to decline, and Zacks says the company lacks the combination of factors typically associated with a likely earnings beat. That is weighing on expectations ahead of the report. Moderna Q3 earnings preview
• Negative Sentiment: William Blair lowered Moderna to Market Perform, while an analyst also reduced the company’s fiscal 2028 EPS estimate. The actions reinforce concerns about the premium valuation, limited near-term earnings visibility and the time required for oncology programs to mature. Moderna rating lowered to Market Perform Moderna FY2028 EPS estimate lowered

Insider Activity

In related news, insider Shannon Klinger sold 3,471 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the transaction, the insider directly owned 74,129 shares of the company’s stock, valued at $10,374,353.55. This trade represents a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jamey Mock sold 34,836 shares of the business’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the transaction, the chief financial officer owned 59,375 shares in the company, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 197,251 shares of company stock worth $33,875,904 over the last quarter. Insiders own 10.80% of the company’s stock.

Moderna Company Profile

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.